10-Q: Pulmonx Corporation Reports Third Quarter 2024 Results: Revenue Growth Amidst Continued Losses

Pulmonx Corporation's third quarter 2024 results show a revenue increase of 15.4% year-over-year, but the company continues to operate at a net loss.

Summary

• Pulmonx Corporation reported a revenue of $20.4 million for the three months ended September 30, 2024, a 15.4% increase compared to $17.7 million in the same period of 2023.
• The company's gross profit was $15.0 million, maintaining a gross margin of 73.7% for the quarter.
• Operating expenses totaled $29.2 million, with research and development expenses at $3.7 million and selling, general, and administrative expenses at $25.4 million.
• Pulmonx reported a net loss of $14.1 million for the quarter, compared to a net loss of $14.9 million for the same period in 2023.
• For the nine months ended September 30, 2024, revenue was $60.0 million, a 21.5% increase from $49.4 million in the same period of 2023.
• The company's net loss for the nine months was $43.2 million, compared to a net loss of $47.0 million for the same period in 2023.
• As of September 30, 2024, Pulmonx had cash, cash equivalents, and marketable securities of $107.8 million and an accumulated deficit of $454.4 million.
• The company's long-term debt was $37.2 million, net of debt discount and issuance costs.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth, the company continues to operate at a loss and has an accumulated deficit. The company also has a debt covenant violation, which is a concern. The company's future success depends on its ability to achieve profitability and manage its debt.

Positives

• Revenue growth of 15.4% in the third quarter and 21.5% for the nine-month period indicates increasing market adoption of Pulmonx's products.
• The company maintained a strong gross margin of 73.7% in the third quarter and 74.0% for the nine-month period.
• The net loss for the third quarter and nine-month period decreased compared to the same periods in the previous year.
• The extension of the interest-only period on the CIBC loan provides additional financial flexibility.
• The company has a substantial amount of cash, cash equivalents, and marketable securities on hand.

Negatives

• The company continues to operate at a net loss, with a $14.1 million loss in the third quarter and a $43.2 million loss for the nine-month period.
• Operating expenses remain high, totaling $29.2 million for the third quarter.
• The company has an accumulated deficit of $454.4 million as of September 30, 2024.
• The company had a debt covenant violation related to minimum cash balance requirements with CIBC, which was cured on October 1, 2024, and a waiver was granted in October 2024.

Risks

• The company's reliance on a single product, the Zephyr Valve, makes it vulnerable to market changes and competition.
• The company's success depends on hospital, physician, and patient adoption of its solution, which may be hindered by various factors.
• Use of the Zephyr Valve involves risks and may result in complications, including pneumothorax or death.
• The company's ability to achieve and maintain adequate levels of coverage or reimbursement for its solution is uncertain.
• The company faces competition from larger companies with more established products and greater resources.
• The company has limited long-term data regarding the safety and effectiveness of its products.
• The company relies on single-source suppliers for critical components, which makes it vulnerable to supply shortages.
• The company's operating results may fluctuate significantly, making future results difficult to predict.
• The company expects to continue to incur net losses and require substantial additional capital.
• The company's products and operations are subject to extensive government regulation and oversight.
• The company may become a party to intellectual property litigation that could be costly and interfere with its ability to sell and market its products.

Future Outlook

Management believes that the company's existing cash, cash equivalents, and marketable securities will allow it to continue operations for at least the next 12 months. The company expects to continue to incur net losses for the next several years and will require substantial additional funding.

Management Comments

• Management believes that the company's existing cash, cash equivalents and marketable securities will allow the Company to continue its planned operations for at least the next 12 months from the date of the issuance of these unaudited interim condensed consolidated financial statements.

Industry Context

The medical device industry is highly competitive and subject to rapid change. Pulmonx is working to establish its solution as a standard of care for severe emphysema, competing with existing treatments like medical management, lung volume reduction surgery, and lung transplantation, as well as other minimally invasive treatments. The company is also working to expand its market share in the face of competition from companies with greater resources and established relationships with pulmonologists.

Comparison to Industry Standards

• Pulmonx's gross margin of approximately 74% is relatively high for a medical device company, suggesting strong pricing power or efficient manufacturing processes. This compares favorably to companies like Intuitive Surgical (ISRG) which has a gross margin of around 68% and Medtronic (MDT) which has a gross margin of around 69%.
• The company's revenue growth of 15.4% in the third quarter and 21.5% for the nine-month period is strong, indicating increasing market adoption of its products. This growth rate is higher than many established medical device companies, such as Stryker (SYK) which has seen revenue growth of around 11% in recent quarters.
• However, Pulmonx's continued net losses are a concern, as many established medical device companies are profitable. For example, both Intuitive Surgical and Medtronic are profitable.
• The company's reliance on a single product, the Zephyr Valve, is a risk, as many successful medical device companies have a diversified product portfolio. Companies like Johnson & Johnson (JNJ) and Abbott (ABT) have a wide range of products across different medical specialties.
• Pulmonx's debt level of $37.2 million is relatively low compared to some larger medical device companies, but the company's debt covenant violation is a concern. Companies like Medtronic have significantly higher debt levels, but they also have much stronger cash flows and profitability.

Management Changes

Legal Proceedings

• The company received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division in connection with an investigation under the Anti-Kickback Statute and False Claims Act.
• The CID requests information and documents regarding the company's relationships with certain health care providers, medical practices, and hospitals in connection with the sales and marketing of the Zephyr Valves and related products and services.
• The company is fully cooperating with the Investigation.

Stakeholder Impact

• Shareholders face the risk of continued losses and potential dilution from future capital raises.
• Employees may be affected by changes in management and potential restructuring.
• Customers (hospitals and physicians) may be impacted by changes in pricing, reimbursement, and product availability.
• Suppliers may be affected by changes in the company's manufacturing and supply chain strategies.
• Creditors may be concerned about the company's debt levels and ability to repay its obligations.

Next Steps

• The company intends to continue to make investments in the development of its products, including ongoing research and development programs.
• The company intends to continue to make significant investments in its sales and marketing organization.
• The company will continue to make investments in research and development efforts to develop its next generation products and support future regulatory submissions.

Key Dates

Keywords

Zephyr Valve, emphysema, COPD, medical device, pulmonology, endobronchial valve, lung volume reduction, healthcare, medical technology, interventional pulmonology